New York, August 25, 2016 -- Moody's Investors Service commented that the Patent Trial and Appeal Board's invalidation of two of Teva's patents on Copaxone 40mg is credit negative. However, there is no change to Teva Pharmaceutical Industires Ltd Baa2 senior unsecured rating or stable outlook.
Vollständigen Artikel bei Moodys lesen